Results 31 to 40 of about 32,704 (143)

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

npj Vaccines, 2020
The RSV Fusion (F) protein is a target for neutralizing antibody responses and is a focus for vaccine discovery; however, the process of RSV entry requires F to adopt a metastable prefusion form and transition to a more stable postfusion form, which ...
Amy S. Espeseth, P. Cejas, Michael P. Citron, Dai Wang, D. Distefano, Cheryl Callahan, Gregory O ’ Donnell, Jennifer D Galli, Ryan Swoyer, Sinoeun Touch, Zhiyun Wen, J. Antonello, Lan Zhang, Jessica Flynn, K. Cox, D. Freed, K. Vora, Kapil Bahl, Andrew H. Latham, Jeffrey S. Smith, Marian E. Gindy, G. Ciaramella, D. Hazuda, C. Shaw, A. Bett   +24 more
semanticscholar   +1 more source

Clinical severity of RSV bronchiolitis

Health Science Reports, 2022
AbstractBackgroundStudies comparing the severity of respiratory syncytial virus (RSV) bronchiolitis to other viruses are inconclusive. Our study aimed to compare the severity of bronchiolitis according to the virus.MethodsData were collected from 1152 infants under one year of age admitted to Children's hospital for Wales, over the winter months of ...
Faris Hussain, Margarita Delgado Thompson, David Vick, Jack West, Martin Edwards   +4 more
openaire   +3 more sources

Comparison of the Xpert Flu/RSV XC and Xpress Flu/RSV Assays [PDF]

Journal of Clinical Microbiology, 2018
Molecular diagnostics for influenza and respiratory syncytial virus (RSV) have become commonplace, and various tests and systems have been cleared by the FDA for use in the United States. We performed a retrospective study to compare the Cepheid Xpress Flu/RSV assay with the Xpert Flu/RSV XC assay, using laboratory-developed tests (LDTs) as the ...
Elena B. Popowitch, Melissa B. Miller
openaire   +2 more sources

RSV genomic diversity and the development of a globally effective RSV intervention

Vaccine, 2021
Respiratory syncytial virus (RSV) is the most common cause of serious lower respiratory tract illness in infants and children and causes significant disease in the elderly and immunocompromised. Recently there has been an acceleration in the development of candidate RSV vaccines, monoclonal antibodies and therapeutics.
Sonnie Kim, Thomas C. Williams, Cecile Viboud, Harry Campbell, Jiani Chen, David J. Spiro   +5 more
openaire   +3 more sources

Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection

Science, 2020
ACHOO!-trophils? Why some individuals come down with a cold in any given year, whereas others are spared, is poorly understood. Habibi et al. exposed volunteers to respiratory syncytial virus (RSV), one of the pathogens responsible for the common cold ...
M. Habibi, R. Thwaites, Meiping Chang, A. Jóźwik, A. Paras, F. Kirsebom, A. Varese, Amber Owen, L. Cuthbertson, P. James, T. Tunstall, D. Nickle, T. Hansel, M. Moffatt, C. Johansson, C. Chiu, P. Openshaw   +16 more
semanticscholar   +1 more source

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

Clinical Infectious Diseases
Background The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season.
Michael G. Ison, Alberto Papi, Eugene Athan, Robert G. Feldman, Joanne M Langley, Dong-Gun Lee, I. Leroux-Roels, F. Martinón-Torres, Tino F. Schwarz, Richard N. van Zyl-Smit, Céline Verheust, N. Dezutter, Olivier Gruselle, L. Fissette, M. David, L. Kostanyan, Veronica Hulstrøm, Aurélie Olivier, M. Van der Wielen, Dominique Descamps   +19 more
semanticscholar   +1 more source

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Human Vaccines & Immunotherapeutics, 2020
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults.
A. Aliprantis, C. Shaw, P. Griffin, N. Farinola, Radha A. Railkar, Xin Cao, Wen Liu, J. Sachs, Christine J Swenson, Heather Lee, K. Cox, Daniel S Spellman, C. Winstead, I. Smolenov, E. Lai, T. Zaks, Amy S. Espeseth, Lori Panther   +17 more
semanticscholar   +1 more source

The ABCs of RSV

The Nurse Practitioner, 2018
Abstract: Respiratory syncytial virus (RSV) is a common viral infection affecting many children in the United States. This seasonal virus is the leading cause of hospitalization of infants and neonates. This article reviews the current recommendations for diagnostic testing, treatment options, and prevention of RSV.
openaire   +4 more sources

A proof of concept for structure-based vaccine design targeting RSV in humans

Science, 2019
Building a better RSV vaccine Respiratory syncytial virus (RSV) causes severe respiratory disease, especially in infants and the elderly. However, attempts to produce effective human vaccines have largely been unsuccessful.
M. Crank, T. Ruckwardt, Man Chen, Kaitlyn M. Morabito, Emily Phung, Pamela J M Costner, L. Holman, S. Hickman, N. Berkowitz, Ingelise J. Gordon, G. Yamshchikov, M. Gaudinski, Azad Kumar, Lauren A. Chang, Syed M. Moin, J. Hill, Anthony T. DiPiazza, Richard M. Schwartz, L. Kueltzo, J. Cooper, Peifeng Chen, Judy A. Stein, Kevin Carlton, J. Gall, M. Nason, P. Kwong, Grace L. Chen, J. Mascola, J. McLellan, J. Ledgerwood, B. Graham   +30 more
semanticscholar   +1 more source

Toward unified molecular surveillance of RSV: A proposal for genotype definition

Influenza and Other Respiratory Viruses, 2020
Human respiratory syncytial virus (RSV) is classified into antigenic subgroups A and B. Thirteen genotypes have been defined for RSV‐A and 20 for RSV‐B, without any consensus on genotype definition.
S. Goya, M. Galiano, Inne Nauwelaers, Alfonsina Trento, P. Openshaw, A. Mistchenko, M. Zambon, M. Viegas   +7 more
semanticscholar   +1 more source